We are delighted to announce a new strategic partnership with Astex Pharmaceuticals alongside the funding of two new projects. With translation as a core priority of the UK DRI’s science vision, the collaboration aims to identify and validate novel pathways and drug targets for neurodegenerative disease – the first step in what may ultimately lead to transformative new treatments for dementia.
Around 850,000 people in the UK have dementia, and the number of people affected will continue to grow as the population ages. With no effective treatments currently available for any of the neurodegenerative conditions that give rise to dementia, this new partnership provides hope for the development of new drugs to transform treatment for people with dementia.
Astex, a subsidiary of Otsuka Pharmaceutical, has a strong track record in discovering drugs for patient populations of high unmet medical need. Its technology platform (Pyramid™) has used a fragment-based drug discovery approach to successfully generate multiple new drug candidates for cancer. Some of these drugs have been discovered and developed in partnership with leading pharmaceuticals companies, including the marketed products Kisqali from Astex’s collaboration with Novartis and Balversa from its collaboration with Janssen. Astex’s drug discovery platform is now being applied to multiple neurodegenerative disease targets.